Rapid and robust B-cell depletion in preliminary results of phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS)

Authors
Category Primary study
ConferenceEuropean Journal of Neurology
Year 2017
This article has no abstract
Epistemonikos ID: a13abfcf192365160da14e1ed87e075e4fffa539
First added on: Apr 29, 2026